Last updated on June 2020

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients


Brief description of study

The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric patients ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was already demonstrated in adults with sickle cell disease. The approach is to extrapolate from the PK/pharmacodynamics (PD) already established in the adult population. The study is designed as a Phase II, multicenter, open-label study.

Clinical Study Identifier: NCT03474965

Find a site near you

Start Over

East Carolina University SC

Greenville, NC United States
2.67miles
  Connect »

East Carolina University SC

Greenville, NC United States
2.69miles
  Connect »

Novartis Investigative Site

Greenville, NC United States
2.69miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.